Yesterday, Salix Pharmaecuticals accepted Valeant’s raised takeover offer of $10.96 billion in cash, ending the bidding war between Endo and Valeant for the gastrointestinal drug maker. Valeant’s new offer of $173 per share is about a 10% increase over its original offer of $158 per share. Valeant also paid $296 million for assets of bankrupt […]

Read More

Pharmaceutical companies are using acquisition to become “pointy,” or more focused. Two recent examples are Bayer and Merck.  Bayer is focusing on over the counter medications by acquiring Merck’s consumer care business for $14.2 billion. On the other hand, Merck has become more streamlined through divestment. As I’ve mentioned before, although divestment means becoming smaller, […]

Read More

Healthcare is a hot industry for both PE and strategic buyers as they navigate new regulatory issues posed by the Affordable Care Act. According to Reuters, healthcare was the second largest industry in the U.S. by deal value for the third quarter of 2013. The New York Times reports the number of private exchanges has […]

Read More

Two major hospital acquisitions announced this summer will result in huge hospital networks and likely create pressure for other hospital deals.  Tenet will buy Vanguard Health for $1.73 billion and Community Health will buy HMA for $3.6 billion. Combined with Vanguard Health, Tenet will become No. 1 or 2 in 19 key markets, including San […]

Read More